Clinical Trials Sponsored by Talaris Therapeutics Inc.

Total 2991 results

Talaris Therapeutics Inc.

Withdrawn

Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis

Multiple Sclerosis
Talaris Therapeutics Inc.

Withdrawn

A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis (FREEDOM-3)

Diffuse Cutaneous Systemic Sclerosis

United States
Talaris Therapeutics Inc.

Terminated

A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation (FREEDOM-1)

Transplanted Organ Rejection

United States
Talaris Therapeutics Inc.

Withdrawn

A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients (FREEDOM-2)

Kidney Transplantation

United States
Talaris Therapeutics Inc.
Duke University

No longer available

Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)

Metachromatic Leukodystrophy

United States
Talaris Therapeutics Inc.
Duke University

Terminated

Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders

Niemann-Pick Disease | Alpha-mannosidosis | Tay Sachs Disease | Sandhoff Disease | Metachromatic Leukodystrophy (MLD) | Hurler-Scheie Syndrome | Hurler Syndrome (MPS I) | Hunter Syndrome (MPS II) | Sanfilippo Syndrome (MPS III) | Krabbe Disease (Globoid Leukodystrophy) | Adrenoleukodystrophy (ALD and AMN) | Pelizaeus...

United States
Talaris Therapeutics Inc.
Northwestern University

No longer available

Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)

Renal Failure

United States
Talaris Therapeutics Inc.
Duke University

No longer available

Single Patient Expanded Access Protocol: Metabolic Boost (Boost)

Metachromatic Leukodystrophy

United States
Talaris Therapeutics Inc.
Duke University

Withdrawn

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

Anemia, Sickle Cell | Thalassemia | Beta-Thalassemia | Bone Marrow Failure Syndromes | Diamond-Blackfan Anemia | Alpha-Thalassemia | Complex and Transfusion-dependent Hemoglobinopathies

United States
Talaris Therapeutics Inc.
Northwestern University

Active, not recruiting

Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion

Renal Failure

United States
Aclaris Therapeutics, Inc.

Completed

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

Atopic Dermatitis

United States
Aclaris Therapeutics, Inc.

Completed

Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

Atopic Dermatitis

United States
Aclaris Therapeutics, Inc.

Completed

A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

Androgenetic Alopecia

United States
Aclaris Therapeutics, Inc.

Completed

Study of A-101 for the Treatment of Seborrheic Keratosis

Seborrheic Keratosis

United States
Aclaris Therapeutics, Inc.

Completed

ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

Alopecia

United States
Aclaris Therapeutics, Inc.

Terminated

A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata

Alopecia Areata

United States
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra

Dermatosis Papulosa Nigra

United States
Aclaris Therapeutics, Inc.

Completed

Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata

Alopecia Areata | Alopecia Totalis | Alopecia Universalis

United States
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

Common Wart

United States
Aclaris Therapeutics, Inc.

Completed

Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

Seborrheic Keratosis

United States
Aclaris Therapeutics, Inc.

Completed

An Open-Label Safety Study of A-101 Solution

Seborrheic Keratosis

United States
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.

Seborrheic Keratosis

United States
Aclaris Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis (SK)

Seborrheic Keratosis

United States
Aclaris Therapeutics, Inc.

Completed

ATI-450 Plus MTX Versus Placebo Plus MTX in Patients With Moderate to Severe Active RA

Rheumatoid Arthritis

United States, Bulgaria, Czechia, Poland
Aclaris Therapeutics, Inc.

Completed

Safety Study of A-101 Topical Solution for the Treatment of Common Warts

Common Wart

United States
Aclaris Therapeutics, Inc.

Completed

Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)

Alopecia Totalis (AT) | Alopecia Universalis (AU)

United States
Aclaris Therapeutics, Inc.

Completed

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses (SK-FAN)

Seborrheic Keratosis

United States
Aclaris Therapeutics, Inc.

Completed

Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea

Rosacea

United States
Aclaris Therapeutics, Inc.

Completed

A Phase2 of A-101 Topical Solution in Subjects With Common Warts

Common Wart

United States
Aclaris Therapeutics, Inc.

Completed

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

Seborrheic Keratosis (SK)

United States
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Solution in Subjects With Common Warts.

Common Warts

United States
Aclaris Therapeutics, Inc.

Terminated

Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

Psoriatic Arthritis

United States, Poland
Aclaris Therapeutics, Inc.

Completed

ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Hidradenitis Suppurativa

United States
Aclaris Therapeutics, Inc.

Terminated

Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)

Cryopyrin-Associated Periodic Syndrome

United States
Aclaris Therapeutics, Inc.

Completed

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

Rheumatoid Arthritis

United States
Aclaris Therapeutics, Inc.

Completed

A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

Vitiligo

United States
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Topical Solution for the Treatment of Common Warts

Common Wart

United States
Aclaris Therapeutics, Inc.

Terminated

ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

Alopecia Areata | Alopecia Totalis | Alopecia Universalis

United States
Aclaris Therapeutics, Inc.

Completed

Study of A-101 Topical Solution for the Treatment of Common Warts

Common Wart

United States
Aclaris Therapeutics, Inc.

Completed

A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis

Atopic Dermatitis

United States
Aclaris Therapeutics, Inc.

Completed

A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis

Seborrheic Keratosis

United States
Talaris Therapeutics Inc.
Northwestern University; Duke University; Regenerex, LLC

Terminated

Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion

Kidney Failure

United States
Washington University School of Medicine
Aclaris Therapeutics, Inc.

Withdrawn

ATI-2231 in Advanced Solid Tumor Malignancies

Advanced Solid Tumor | Advanced Solid Tumor Malignancies

United States
Global Coalition for Adaptive Research
Bayer; Kazia Therapeutics Limited; Biohaven Pharmaceuticals, Inc.; Kintara Therapeutics... and other collaborators

Recruiting

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)

Glioblastoma

United States, France, Germany, Canada, Australia, Switzerland
Qlaris Bio, Inc.

Not yet recruiting

Qlaris Phase 2 Study in NTG Patients

Glaucoma | Normal Tension Glaucoma (NTG) | Low-Tension Glaucoma, Bilateral | Low-Tension Glaucoma, Unspecified Eye

Korea, Republic of, Philippines
Qlaris Bio, Inc.

Completed

A Study to Evaluate Safety and Tolerability of QLS-101 in NTG

Normal Tension Glaucoma (NTG)

United States
BlackThorn Therapeutics, Inc.
Neumora Therapeutics, Inc.

Completed

Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo

Major Depressive Disorder

United States
Sirion Therapeutics, Inc.
ReVision Therapeutics, Inc.

Completed

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Geographic Atrophy | Dry Age Related Macular Degeneration
Qlaris Bio, Inc.

Recruiting

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

Glaucoma | Open-angle Glaucoma (OAG) | Ocular Hypertension (OHT)

United States
Qlaris Bio, Inc.

Recruiting

Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients

Primary Open Angle Glaucoma of Both Eyes | Primary Open Angle Glaucoma (POAG) | Primary Open-Angle Glaucoma, Unspecified Eye | Ocular Hypertension (OHT)

United States

Clinical Trials Sponsored by Talaris Therapeutics Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations